Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on LinkedIn:
“ROSELLA shows relacorilant plus nab-paclitaxel improves OS (HR 0.65) and PFS (HR 0.70) in platinum-resistant ovarian cancer.
No biomarker selection required. Manageable but higher grade ≥3 AEs.”
Title: Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
Authors: Domenica Lorusso, Laurence Gladieff, David M O’Malley, Jae-Weon Kim, Gabriel Garbaos, Anna Fagotti, Lucy Gilbert, Linda Mileshkin, Stanislas Quesada, Elizabeth Hopp, Yong Jae Lee, Ana Oaknin, Mariana Scaranti, Byoung-Gie Kim, Andrew Clamp, Christina Prillaman, Connie Diakos, Andrea Bagaméri, Aliza L Leiser, Vanda Salutari, Bradley J Monk, Philippe Follana, Emily McClung, Vittoria Carbone, Brian Slomovitz, Elena Giudice, Maria Chiara Cannizzaro, Laurène Gavoille, Alix Devaux, Paolo Scollo, Giuseppa Scandurra, Chiara Cassani, Grazia Artioli, Toon Van Gorp, Ana Santaballa, Lyndah K Dreiling, Amanda Kesner-Hays, Iulia Cristina Tudor, Adrian M Jubb, Nicoletta Colombo, Alexander B Olawaiye
Other articles featuring Elvina Almuradova on OncoDaily.